Who are Acrigen's investors?

Acrigen's investors include Berkeley Catalyst, Dolby Family Ventures.

How much funding has Acrigen raised?

Acrigen has disclosed $775K raised across 1 round.

Where is Acrigen headquartered?

Acrigen is headquartered in Kensington, US.

Acrigen

Kensington, US · Founded 2019 · 2 known investors

Find your way into Acrigen

Paths you didn't know you had: your email and LinkedIn already hold routes to the Acrigen team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Acrigen develops precision gene editing systems based on CRISPR, using novel αCas and μCas nuclease libraries paired with engineered anti-CRISPR (ErAcr) proteins to reduce off-target edits. The technology is aimed at human therapeutics for genetic diseases and is offered for licensing.

Biotech Deep Tech Healthtech

Founders & leadership

Joseph Bondy-DenomyNamed on SEC filing

David RabukaNamed on SEC filing

Karen BoeziNamed on SEC filing

Investors · 2

Berkeley Catalystlisted by Berkeley CatalystBerkeley

How we know: the VCSheet dataset · Not right? Tell us

Dolby Family Ventureslisted by Dolby Family VenturesSan Francisco

How we know: Dolby Family Ventures's portfolio page · the VCSheet dataset · Not right? Tell us

Reported raises · per SEC filings

Form D private placements

$775K disclosed across 1 round · 2019

▶$775KraisedJul 2019 · 9 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Joseph Bondy-DenomyDirector
David RabukaExecutive Officer, Director, Promoter
Karen BoeziDirector

Offering amount: $1M
Amount sold: $775K
First sale: Jun 2019
Incorporated: Corporation, Delaware, 2019
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 5

IRIS MEDICINEIris Medicine is an early-stage biotech developing RNA therapies based on its small binding RNA (sbRNA) platform, which uses cooperative RNAi binding to selectively silence mutant genes carrying expanded pathologic repeat sequences while preserving healthy alleles. Its lead programs target repeat expansion disorders including Huntington's Disease, C9orf72 ALS, and the Spinocerebellar Ataxias.

Generate BiomedicinesGenerate:Biomedicines develops protein-based therapeutics using artificial intelligence and machine learning in a field it calls Generative Biology, combining computational protein design with biological engineering. The company creates new drugs on demand across diverse biologic modalities for immunology, oncology, infectious disease, and vaccines.

Estrigenix TherapeuticsEstrigenix Therapeutics is a pharmaceutical company developing first-in-class therapeutics based on estrogen biology to treat and prevent hot flashes and dementia in post-menopausal women. It aims to license its lead compounds to pharmaceutical companies after phase 2 clinical trials, offering menopause symptom relief without the breast cancer and stroke risks of traditional hormone replacement therapy.

PrecigenPrecigen is a biopharmaceutical company developing gene and cell therapies, including PAPZIMEOS (zopapogene imadenovec-drba), an FDA-approved immunotherapy for adults with recurrent respiratory papillomatosis. The company focuses on immuno-oncology and immunotherapy treatments delivered via subcutaneous injection.

Algen BiotechnologiesAlgen Biotechnologies discovers and develops small molecule therapeutics for cancer and inflammatory diseases using CRISPR, RNAi, and machine learning to decode functional gene networks and predict drug responses.

Companies working in the same space as Acrigen.

Non-dilutive funding · 5 SBIR/STTR awards

Federal grants — no equity taken

Agency	Phase	Year	Amount
National Science Foundation	Phase II	2022	$1M
National Institutes of Health (NIH)National Institutes of Health	Phase I	2022	$256.6K
National Institutes of Health (NIH)National Institutes of Health	Phase ISTTR	2021	$256.6K
National Institutes of Health (NIH)National Institutes of Health	Phase I	2020	$252.1K
National Science Foundation	Phase I	2020	$225K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

Frequently asked questions

What does Acrigen do?: Acrigen develops precision gene editing systems based on CRISPR, using novel αCas and μCas nuclease libraries paired with engineered anti-CRISPR (ErAcr) proteins to reduce off-target edits. The technology is aimed at human therapeutics for genetic diseases and is offered for licensing.
Who are Acrigen's investors?: Acrigen's investors include Berkeley Catalyst, Dolby Family Ventures.
How much funding has Acrigen raised?: Acrigen has disclosed $775K raised across 1 round.
Where is Acrigen headquartered?: Acrigen is headquartered in Kensington, US.